To address this possibility, we assessed the impact of CHMP5 deficiency on T-ALL cell sensitivity to killing by chemotherapy and measured the viability of control (CT) and CHMP5-deficient (KD) human T-ALL cells after cytarabine (AraC) treatment in vitro. The gene discussed is CHMP5; the disease is acute lymphoblastic leukemia.